Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 9;12:2661–2675. doi: 10.2147/OTT.S197682

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Cui et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

MiR-17-DC reduces T cell proliferation and favored Treg expansion. Pretreated BMDCs were added at different densities (10:1, 20:1, 50:1 and 100:1) to T cells for 3 days and incubated with BrdU (24 hours) to quantify proliferation. (A) LPS-stimulated DCs triggered strong T lymphocyte proliferation, whereas this response was suppressed by miR-17-5p pretreatment. (B) Tregs (CD4⁺CD25⁺Foxp3⁺) were decreased by LPS stimulation but was increased by miR-17-DCs. At high concentration, miR-17-DC-stimulated T cells displayed higher Tregs percentage than imDCs. ^aCompared to imDCs. ^bCompared to N+LPS. **P<0.01, ***P<0.001.

Abbreviations: BMDC, bone marrow-derived dendritic cell; N, scramble; imDC, immature dendritic cell; LPS, lipopolysaccharide; Treg, regulatory T cells.